Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GD2-28z CAR T cells
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intrathecal, Intratumoral
01
Overview
GD2-28z CAR T cells are an adoptive cell therapy consisting of T cells engineered to express a chimeric antigen receptor (CAR) targeting the disialoganglioside GD2. The CAR construct typically utilizes the 14G2a single-chain variable fragment (scFv) for antigen recognition, coupled with a CD28 costimulatory domain and a CD3-zeta (ζ) signaling domain. GD2 is highly expressed on various neuroectoderm-derived tumors, including neuroblastoma, osteosarcoma, melanoma, and certain brain tumors like diffuse intrinsic pontine glioma (DIPG). The inclusion of the CD28 domain is intended to enhance T cell expansion and persistence upon antigen encounter. This specific construct has been widely used in academic research and early-phase clinical trials, notably by investigators at the National Cancer Institute and Stanford University.
- Other names
- GD2-CD28-CD3z CAR T cellsGD-2-CD28-CD3z CAR T cellsGD 2-CD28-CD3z CAR T cells14G2a-28z CAR T cells
02
Targets
GD2
Beyond the preview
Go deeper on GD2-28z CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GD2-28z CAR T cells.